Patent intelligence · US
US 11673902
Isoindolinone and indazole compounds for the degradation of EGFR
Isoindolinone and indazole compounds for the degradation of EGFR
Patent details — US 11673902
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 13, 2023
- Expiration
- Jun 8, 2043
- Applicant
- C4 THERAPEUTICS, INC.
- Claims
- 29
- CPC classes
- A61K, A61K31/427, A61K31/496, A61K31/506
Quick answer
US 11673902 (Isoindolinone and indazole compounds for the degradation of EGFR) is held by C4 THERAPEUTICS, INC.. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- C4 THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/427, A61K31/496, A61K31/506, A61K31/5377, A61K47/10
More from C4 THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421220
Bicyclic-substituted glutarimide cereblon binders
granted -
US 12371442
Isoindolinone and indazole compounds for the degradation of EGFR
granted -
US 12227504
Spirocyclic compounds
granted -
US 12180225
N/O-linked degrons and degronimers for protein degradation
granted -
US 12157735
Compounds for targeted degradation of BRD9
granted -
US 12091397
Dihydroquinolinones for medical treatment
granted -
US 12076405
Heterocyclic degronimers for target protein degradation
granted -
US 12048747
Substituted piperidine Degronimers for Target Protein degradation
granted
Frequently asked questions
What is US patent 11673902?
US 11673902 (Isoindolinone and indazole compounds for the degradation of EGFR) is held by C4 THERAPEUTICS, INC.. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11673902?
C4 THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 11673902 expire?
Our index shows an expiration date of Jun 8, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.